Urotensin receptor antagonists ii.

A compound of Formula (I); Formula (I) wherein: when A is present, then G is selected from hydrogen, C1-8 alkyl, C2-8 alkenyl, C3-14 cycloalkyl or a -C [(R1) (R11)] - LD: being C1-8 alkyl optionally substituted with one, two or three fluoro substituents and C3-14 cycloalkyl optionally substituted with one, two or three substituents being C 1-3 alkyl; or, when A is absent and R2 is other than benzyloxymethyl, then G is C1-8alkoxy or heterocyclyloxy, C1-8 alkoxy substituted by the one being amino, (C1-8 alkyl) amino, di (C1-8 alkyl) amino, (benzyl) amino or [(benzyl) (C1-4alkyl)] amino, and the heterocyclyloxy is optionally substituted on heterocyclyl with one, C1- March 2 or three substituents; R1 is selected from the group consisting of hydrogen, C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl; R11 is selected from the group consisting of hydrogen, C1-8alkyl and cyclopropyl; L is absent or C1-4alkylene; D is aryl (other than naphthalen-2-yl), C3-14 cycloalkyl, C5-14 cycloalkenyl, heterocyclyl or heteroaryl, the aryl and heteroaryl optionally substituted with one, two, three or four substituents being independently selected from the group consisting of C1-3alkyl, C1-3alkoxy, C2-8alkenyl, C2-3 alkenyloxy, hydroxy, C1-3 alkylthio, fluorine, chlorine, cyano, C1-3 alkylcarbonyl, (C1-3 alkylcarbonyl) amino, ( C1-3) alkylamino, di (C1-3 alkyl) amino and C3-14 cycloalkyl, C3-14 cycloalkyl the optionally substituted with one, two, three or four C1-3alkyl substituents, provided that D is other 2-hydroxy 5-chloro-phenyl, 3-methoxyphenyl, 4-ethyl-phenyl, 6,6-dimethylbicyclo [3.1.1] hept-2-en-2-yl-methyl, cyclohex-3-enyl, 2,6-dichlorophenyl and 2-chloro-4-fluoro-phenyl; A is an optionally present biradical selected from the group consisting of a-1, a-2 optionally unsaturated a-3, a-4, a-5 optionally unsaturated a-6, wherein, the bottom of A it is attached, relative to the nitrogen atom of Formula (I), to the 3 or 4 position of the benzene ring of Formula (I); being a-1, a-2, a-3, a-4 and a-5 optionally substituted with one to two substituents C1-4alkyl; with the proviso that A is other than cis- (1,2) -cyclohexyldiamino; R4 is hydrogen or C1-8 alkyl; L2 is absent or -C (R2) (R5) - (CR6R7) r-, wherein r is 0, 1 or 2; and wherein R5, R6, and R7 are independently hydrogen or C1-3 alkyl; with the proviso that L2 is other than -CH (R-carboxymethyl) -; R2 is selected from the group consisting of a heteroaryl that is not fused to another ring, phenyl and C1-6 alkyl, phenyl optionally substituted with (R200-C1-6alkyl) amino, or [(hydroxysulfonyl) (Ra) being ] amino, and wherein the C1-8 alkyl optionally substituted with carboxy, hydroxy, R200, NRaRb, C1-6alkoxy, R200-C1-6alkoxy, R200-oxy, aminocarbonyl, carboxy-C1-6alkoxy, aminocarbonyl-C1 -6, (C1-8 alkyl) aminocarbonyl, di (C1-8 alkyl) aminocarbonyl, [(R200-C1-6alkyl) (Ra)] amino, (C1-6 alkylcarbonyl) amino, (trihalo C1-4 alkylcarbonyl ) amino, (C1-6 alkylcarbonyl R200-) amino, (C1-6 alkoxycarbonyl) amino, (R200-C1-6 alkoxycarbonyl) amino, (C1-6alkoxy-C1- alkylcarbonyl 9) amino, (R200-carbonyl) amino , (amino-alkylcarbonyl 1-6C) alkylamino, [(C1-6alkyl) amino-C1-6 alkylcarbonyl] amino, [di (C1-6 alkyl) amino-C1-8 alkylcarbonyl] amino, (alkylcarbonyl 1-6 acetonitrile-carbonyl) amino 5, ureido, thioureido, acetamidino, guanidino, {[(R200) ​​(Ra)] aminocarbonyl- (Rc)} amino, [(R200-oxycarbonyl) (Ra)] amino, [(R200) ​​(Ra)] aminocarbonyloxy, aminosulfonyl, C1-6 alkylsulfonyl, (C1-6 alkylsulfonyl) amino, (R200-C1- 6 alkylsulfonyl) amino, (R200- alquenilsulfonil C2-6) amino, (C1-8 alkylsulfonyl C1-6 alkylsulfonyl) amino, R200-sulfonyloxy, aminosulfonyloxy, (C1-6alkyl) aminosulfonyloxy, di (C1-6alkyl) aminosulfonyloxy, aminosulfonylamino, (C1- 6 alkyl ) aminosulfonylamino, [di (C1-6alkyl) aminosulfonyl] amino, [(hydroxysulfonyl) (Ra)] amino, [(R200-oxisulfonil) (Ra)] amino, [(R200-sulfonyl) (Ra)] amino, [ (R200) ​​(Ra)] aminosulfonyloxy, or ({[(R200) ​​(Ra)] aminosulfonyl} (Rc)) amino; Ra and Rc are independently selected from the group consisting of hydrogen and C1-6alkyl; and Rb is hydrogen, C1-6 alkyl, C6-10 aryl, heteroaryl, C3-8cycloalkyl or heterocyclyl; R200 is C6-10aryl, heteroaryl, C3-8cycloalkyl, or heterocyclyl, each optionally substituted with one, two or three substituents independently selected from the group consisting of C1-4alkyl, trihalo-C1-4alkyl, C1 -4, trihalo-C1-4alkoxy, C1-6 alkylcarbonyl, C1-9 alkoxycarbonyl, (C1-6 alkylcarbonyl) amino, C1-6 alkylsulfonyl, hydroxysulfonyl, aminosulfonyl, chloro, fluoro, bromo, aryl, heteroaryl, aryl- C1-6, arylsulfonyl and heteroaryl-sulfonyl, heterocyclyl optionally substituted with one, two or three oxo substituents; B is C6-10aryl, tetralinyl, indanyl or heteoarilo selected from the group consisting of pyridin-2-yl, pyridin-4-yl, pyrazol-4-yl yl pyrimidin-5-pyrimidin-4-yl, pyrazin-2-yl, imidazol-1-yl, thien-2-yl, isoquinolinyl, indolyl, quinolinyl and thiazol-5-yl, wherein B is optionally substituted with one, two or three substituents independently selected from the group consisting of alkyl C1-4, C1-4alkoxy, C (C1-4) fluorinated, halogen, cyano, hydroxy, aminocarbonyl, alkylaminocarbonyl (1-4C) alkyl, di (C1-4) aminosulfonyl, alkylaminosulfonyl (C1-4), I dialkylaminosulfonyl (1-4C) alkyl, hydroxysulfonyl, aminosulfonylamino, alkylaminosulfonylamino (1-4C) dialkylaminosulfonylamino (C1-4), aminosulfonyloxy, (C1-4) alquilaminosulfoniloxi and di (C1-4) alquilaminosulfoniloxi, with the proviso that when B is selected from the group consisting of C6-10aryl, tetralinyl, indanyl, thien-2-yl, and indolyl, then B is independientement and substituted with two to three substituents selected 30 from the group consisting of C1-3alkoxy and hydroxy, provided that when B is phenyl substituted in the 3,4-, 3,5- or 4,5 positions with unbranched C1-3alkoxy substituent at each position, then phenyl may be optionally further substituted in 3, 4 or 5 remaining open position with a substituent C1-3alkoxy or additional hydroxy and with the proviso that B is other than 3-hydroxy-4-methoxyphenyl and 3- (n-propyloxy) -4-methoxy-phenyl; E is hydrogen, halogen, C1-3 alkoxy, C2-5 alkyl-RE, or -CH = CH-C0-3 alkyl RE; RE is selected from the group consisting of carboxy, amino, (C1-6 alkyl) amino, di (C1-6 alkyl) amino, aminocarbonyl, (C1-6 alkyl) aminocarbonyl, di (C1-6 alkyl) aminocarbonyl, (alkyl C1-6) carbonylamino, C1-6alkoxycarbonylamino, aminocarbonyl (C1-6) alkyl, ureido, thioureido, aminosulfonyl, C1-6alkylsulfonyl, C1-6alkylsulfonylamino, aminosulfonyloxy, (C1-6alkyl) aminosulfonyloxy, di (C1-6alkyl ) aminosulfonyloxy, aminosulfonylamino, (C1-6alkyl) aminosulfonylamino, di (C1-6alkyl) aminosulfonylamino, (R200) ​​(Ra) aminocarbonyl- (Rc) amino, R200carbonilamino, R200oxicarbonil- (Ra) amino, (R200) ​​(Ra) aminocarbonyloxy, R200oxisulfonil- (Ra) amino, R200sulfonil- (Ra) amino, (R200) ​​(Ra) aminosulfonyloxy, and (R200) ​​(Ra) aminosulfonyl- (Rc) amino; X and Y are independently O or S; and enantiomers, diastereomers, tautomers, solvates, and pharmaceutically acceptable salts thereof.